Best Chemotherapy doctors: TOP 123 doctors

• Specializes in cancer immunotherapy and targeted therapies for chemotherapy.
• Trained in Turkey and at NATO medical facilities.
• Member of the Turkish Medical Oncology Association.
• Professor at Istanbul Okan University, teaching medical oncology.
• Over 20 years of experience in medical oncology.

• Specializes in chemotherapy for breast, colorectal, urogenital cancers.
• Trained in Turkey, extensive experience since 2003.
• Member of the Turkish Medical Oncology Society.
• Uses targeted therapy and immunotherapy in chemotherapy.
• Certified in medical oncology and internal medicine.

• Dr. Serdar Turhal specializes in chemotherapy for breast cancer with over 20 years of experience.
• Trained in the USA: San Francisco, Birmingham, Yale University, Mount Sinai, New York.
• Member of ASCO, ESMO, EORTC, BUOn, Turkish Society of Oncology.
• Authored 150 articles in international oncology publications.
• Focuses on prognostic factors and treatment of gastrointestinal tumors.

• Dr. Serkan Keskin specializes in chemotherapy, targeted therapy, and immunotherapy.
• Ranked first in the Medical Oncology Proficiency Exam in Turkey in 2012.
• Member of American Society of Clinical Oncology and European Society of Medical Oncology.
• Published 42 articles in international journals on oncology topics.
• Received Best Poster Award at the 19th National Cancer Congress in 2011.

• Dr. Mustafa Solak uses targeted therapy and immunotherapy as part of his cancer treatment strategies.
• His international practice includes work in the United States and Turkey.
• He is certified by Hacettepe University Cancer Institute.
• Dr. Solak is a member of international oncology societies.
• He specializes in treating breast, testicular, and gastrointestinal cancers.

• Specializes in cancer immunotherapy and targeted therapies for chemotherapy.
• Trained in Turkey, the United States, Israel, and the United Kingdom.
• Certified by the European Society of Medical Oncology (ESMO).
• Member of ESMO and the European School of Oncology (ESO).
• Fluent in English, Turkish, and conversational Russian.

Assoc. Prof. Dr. Oğuzhan BABACAN completed his undergraduate, specialty and sub-specialty education at GATA Military Medical Faculty/Ankara. After becoming a specialist in Pediatrics, he worked in the field of Social Pediatrics for two years, where Healthy Baby Monitoring and vaccine follow-up were carried out. Then, she completed her subspecialty training in Pediatric Hematology and Oncology and continued her studies in the field of pediatric blood and cancer diseases. In addition to the treatment of children suffering from leukemia, lymphoma, solid tumors and other blood diseases, she has been working in the Bone Marrow Transplantation (Transplant) Unit for 13 years in Allogeneic (unrelated and intrafamilial), Autologous (from the patient himself) and Haploidentical (partially HLA compatible) hematopoietic stem cell transplantation. In 2018, he received the title of Associate Professor in the field of Pediatric Hematology and Oncology Science/Art.

MEDICAL AREAS OF INTEREST

Healthy baby follow-up and vaccinations

Lymph node enlargement

Pediatric patients with anemia (anemia)

Leukemia

Lymphoma

Bone Marrow Transplant

ITP

Thalassemias

Hemophiliacs

Solid tumors

Hemangioma

Childhood blood disorders

Children with frequent infections

Fever of unknown origin

Malnutrition in children

Prof. Şeref Kömürcü is an ECFMG and ESMO-certified medical and breast oncologist with over 20 years of experience. He specializes in solid cancer, breast cancer, colorectal and lung cancer treatment and has held teaching and scientific positions throughout his career. He is a member of several professional organizations.

• Over 20 years of experience in chemotherapy, using targeted therapy and immunotherapy techniques.
• International training in Turkey, specializing in medical oncology and chemotherapy methods.
• Member of the European and American Clinical Oncology Associations.
• Published over 40 articles on cancer treatment, including advancements in chemotherapy.
• Has been a Professor in medical oncology since 2011.

• Creates personalized chemotherapy plans tailored to individual patient needs.
• Received international training in Turkey, which enhanced expertise in chemotherapy treatments.
• Member of the European Society for Medical Oncology and the Turkish Society of Medical Oncology.
• Recipient of an Oncology Research Award from the Turkish Medical Oncology Association.
• Authored over 20 papers and 10 book chapters on medical oncology.

• Dr. Ahmet Belici uses targeted therapy and immunotherapy as part of his cancer treatment strategies.
• He has received training in the United States and Germany.
• Ranked among the top oncologists in Turkey for sarcoma and lung cancer.
• Certified by the European Society for Medical Oncology (ESMO).
• Member of the American Society of Clinical Oncology (ASCO).

• Utilizes targeted drug therapy and combination chemotherapy techniques.
• Trained in Germany, with additional oncology specialization in the USA.
• Member of the German Society of Gastroenterology.
• Certified in internal medicine and gastroenterology.
• Authored over 130 publications in oncology and gastroenterology.

• Specializes in intraperitoneal chemotherapy for peritoneal carcinomatosis.
• Trained in the USA, Spain, and Croatia.
• Certified by the American Board of Surgery.
• Member of the American College of Surgeons and Society of Surgical Oncology.
• Performed over 1300 surgeries, including chemotherapy procedures.

Dr. Ofer Merimsly is the best sarcoma, lymphoma, and lung cancer doctor within Israel and in the world. Also specializes in Whipple surgery treatment for patients with pancreatic cancer. Head of the National Center for sarcomas of bone and soft tissues of the Tel Aviv Medical Center Sourasky (Ichilov).

Specialty:

• Treatment of all types of lung cancer and thoracic organs
• Treatment of all types of sarcomas of bone and soft tissue
• Treatment stromal tumors of the gastrointestinal tract

Education and specialization:

• Higher medical education, graduated the Medical Faculty of the Hebrew University of Jerusalem, Israel
• Residency in General Oncology and Radiotherapy
• Training in the field of radiotherapy and brachytherapy at New York Hospital, USA
• Special refresher course for the treatment of tumors of the skeleton and soft tissues, Paris. France

Membership:

• President of the Society of oncologists and radiotherapists Israel
• The American Scientific Cancer Society
• European scientific medical organization
• European Society of Oncology of the musculoskeletal system
• International Society for the treatment of tumors of the connective tissue

Dr. Pelles Sharon is an oncologist known for her skill in advanced cancer treatments and clinical research. She has led important studies on how cancer patients view and understand clinical trials. Her work has helped improve patient involvement and outcomes.

Dr. Sharon performs surgeries for colon and stomach cancer, HIPEC, SIRT therapy, and Whipple surgery. She also offers modern treatments such as immunotherapy, targeted therapy, and chemoembolization. She is respected for her high success rates and dedication to evidence-based care.

One of the best cancer specialists in Europe, educator, and cancer researcher, President of the Central European Cooperative Oncology Group (CECOG).
Has published over 600 scientific papers on cancer treatment.

• Specializes in chemotherapy, radiotherapy, and biological cancer therapy for various cancers.
• Educated in the UK, Israel, and Georgia.
• Member of the European Society for Medical Oncology.
• Member of the American Society of Clinical Oncology.
• Lecturer at Tel Aviv University with over 30 published articles on cancer treatment.

• Specializes in administering intravenous and oral chemotherapy.
• Trained in Germany, with international exposure in the USA and UK.
• Ranked as a top oncologist by Focus magazine in Germany.
• Certified by the German Board of Oncology and Hematology.
• Member of the German Cancer Society and European Oncology Society.